# Emdogain (Enamel Matrix Derivative) — What it is, how it’s…
Page Info
Writer Joshuaa
Hit 16 Hits
Date 26-02-02 15:04
Content
# Emdogain (Enamel Matrix Derivative) — What it is, how it’s used, and what to expect
# 엠도게인(Emdogain, Enamel Matrix Derivative) — 정체·시술 방식·효과·주의점
---
## English
### 1) What “Emdogain” is
**Emdogain** is a periodontal regenerative material based on an **enamel matrix derivative (EMD)**—a protein mixture originally involved in tooth root development. Clinically, it’s applied to a cleaned root surface during periodontal surgery to help regenerate components of the periodontium such as **cementum, periodontal ligament, and alveolar bone**. ([straumann.com][1])
A practical way to think about it:
* It’s **not a “gum filler.”**
* It’s a **biologic regenerative adjunct** used in specific surgical cases where regeneration is plausible.
---
### 2) What it’s used for (typical indications)
Product/clinical materials commonly describe use in:
* **Intrabony defects** (vertical bone defects around teeth)
* **Class II furcation defects** (bone loss between roots of multi-rooted teeth)
* **Recession defects** (selected cases, often combined with flap techniques) ([straumann.com][1])
These are not “all gum problems.” They are specific defect types where regeneration is surgically attempted.
---
### 3) How it’s applied (high-level surgical workflow)
A typical workflow described in product information looks like:
1. **Raise a flap** to access the defect
2. **Thoroughly clean/debride** the root surface
3. **Condition the root surface** with EDTA gel (often sold as PrefGel) for a short period, then rinse
4. **Apply Emdogain** onto the prepared root/defect area
5. **Suture** for stable wound closure ([straumann.com][1])
Why these steps matter:
* Regeneration is very sensitive to **root surface cleanliness** and **wound stability** (micro-movement and contamination reduce success).
---
### 4) Does it work? (what evidence generally shows)
Evidence syntheses and systematic reviews report that, for **intrabony defects**, EMD/Emdogain provides statistically significant clinical improvements compared with open-flap debridement or controls, including gains in clinical attachment and reductions in probing depth at around 1 year. ([guiasclinicas.fundaciondental.es][2])
A major evidence summary (Cochrane-style review work) also reports EMD can show **similar clinical results to guided tissue regeneration (GTR)** while being simpler to use and associated with fewer complications in the studied trials, with no serious adverse reactions reported in those trials. ([PMC][3])
**What “works” means in reality**
* Usually: improved probing depth/attachment level + radiographic bone fill trends
* Not usually: “the gum grows back perfectly everywhere”
* Outcomes depend heavily on defect morphology, surgical technique, infection control, and patient factors (especially smoking and oral hygiene).
---
### 5) Safety, contraindications, and common complications
**Contraindications / caution situations** described in safety documentation include (examples):
* Uncontrolled diabetes or uncontrolled systemic disease
* Conditions/treatments compromising wound healing (e.g., immunosuppression, radiation)
* Chronic high-dose steroid therapy
* Bone metabolic diseases
* Infection or vascular impairment at the surgical site ([straumann.com][4])
**Side effects / complications**
Clinical documents note that adverse events reported tend to be **procedure-related** (bleeding, swelling, pain, inflammation) and that serious events are uncommon in trials; however, complications can occur as with periodontal surgery. ([PMC][3])
**Allergy / sensitivity**
Because EMD products are biologic derivatives, **hypersensitivity/allergic reactions are possible** (rare), and a known allergy to components would be a key red flag. (This is generally addressed in IFU/safety documentation language around adverse events and precautions.) ([hasystems.co.il][5])
Operationally, the biggest “risk” is often not systemic—it's **local failure of regeneration** due to contamination, flap instability, or poor plaque control.
---
### 6) Practical “should I do it?” decision logic (non-sales, clinical realism)
Emdogain tends to make sense when:
* The tooth is worth saving (strategic tooth)
* The defect type is suitable (especially intrabony defects)
* The clinician can achieve stable primary closure
* The patient can maintain excellent plaque control during healing
It tends to be less attractive when:
* The site cannot be kept clean during healing
* Severe systemic factors compromise wound healing (see contraindications)
* The defect morphology is unfavorable for regeneration
* Mobility/occlusion issues are uncontrolled
---
### 7) Implementation tips (for website owners running dental content pages)
If you publish health/dental info pages about Emdogain:
* Avoid absolute claims (“guaranteed regeneration”).
* Clearly separate **indications** (intrabony/furcation/recession) from general gum disease.
* Include a short “risks/contraindications” section (uncontrolled diabetes, immunosuppression, etc.) sourced from official docs. ([straumann.com][4])
This reduces misinformation risk and improves trust.
---
## 한국어
### 1) 엠도게인(Emdogain)이 뭔가
**엠도게인(Emdogain)**은 치주 재생 치료에 쓰이는 **법랑질 기질 유도체(EMD, Enamel Matrix Derivative)** 기반의 생물학적 재생 재료다. 치주 수술 중에 **깨끗이 정리한 치근면/골결손 부위**에 도포해서, **백악질·치주인대·치조골** 같은 치주조직 재생을 돕는다는 컨셉으로 사용된다. ([straumann.com][1])
핵심은 이거다:
* 잇몸을 “메우는” 게 아니라
* 특정 결손 형태에서 “재생”을 시도하는 **수술 보조 재료**다.
---
### 2) 어떤 경우에 쓰나(대표 적응증)
공식/제품 안내 자료에서 흔히 다루는 적용 부위는:
* **치조골 내 골결손(인트라보니, intrabony defects)**
* **2도 치근이개부 병소(Class II furcation)**
* **치은 퇴축(recession defects)**(선택적 케이스에서 술식과 함께) ([straumann.com][1])
즉 “치주염이면 무조건 엠도게인”이 아니라, **재생이 가능한 결손 형태**가 전제다.
---
### 3) 시술은 어떻게 진행되나(큰 흐름)
제품 안내서에서 설명되는 전형적인 흐름은:
1. 결손 부위 접근을 위해 **잇몸 절개/판막 형성**
2. 치근면·결손부의 **염증 조직/치석/오염 제거(디브리드먼트)**
3. EDTA 젤(예: PrefGel)을 일정 시간 적용 후 **세척**
4. 결손부에 **엠도게인 도포**
5. **봉합**으로 상처를 안정화 ([straumann.com][1])
왜 이렇게 하냐:
* 재생은 “약 바르면 끝”이 아니라, **치근면 컨디셔닝 + 상처 안정성(미세 움직임 최소화) + 청결 유지**가 결과를 크게 좌우한다.
---
### 4) 효과는 어느 정도인가(근거가 말하는 범위)
무작위 임상시험을 모아 분석한 리뷰/메타분석에서는, 특히 **intrabony 결손**에서 EMD가 단순 판막수술(또는 대조) 대비 **부착수준 개선, 치주낭 깊이 감소** 등의 유의미한 임상 개선을 보였다고 정리한다. ([guiasclinicas.fundaciondental.es][2])
또 다른 종합 근거에서는 EMD가 **GTR(유도조직재생술)**과 유사한 임상 결과를 보이면서도 술식이 단순하고 합병증이 적었다는 취지로 요약되며, 포함된 시험들에서는 심각한 이상반응이 보고되지 않았다고 정리한다. ([PMC][3])
현실적으로 “효과”의 의미:
* 치주낭 깊이(프로빙) 개선, 부착 수준 개선, 방사선상 골충전 경향
* 다만 “모든 부위에서 새 잇몸이 완벽히 복원” 같은 보장은 아니다.
* 결손 형태, 술자 숙련도, 봉합/판막 안정, 감염관리, 환자 위생이 성패를 가른다.
---
### 5) 부작용·금기·실패 패턴(운영자/환자 모두 알아야 하는 부분)
**금기/주의 상황 예시(공식 안전문서에 포함되는 범주)**
* 조절되지 않는 당뇨 등 **전신질환이 조절되지 않는 경우**
* 상처 치유를 방해하는 상태/치료(면역억제, 방사선 등)
* **고용량 스테로이드 장기요법**
* 골대사 질환
* 수술 부위 감염 또는 혈류장애 ([straumann.com][4])
**이상반응/합병증**
* 대부분은 치주 수술에 동반 가능한 **출혈, 부종, 통증, 염증** 같은 “시술 관련” 반응이 중심으로 보고되며, 임상시험 기반 요약에서는 심각한 이상반응이 흔하지 않았다고 정리된다. ([PMC][3])
**실패가 일어나는 가장 흔한 이유(현장형)**
* 환부가 오염됨(플라그 컨트롤 실패)
* 봉합이 불안정하거나 판막이 열림(상처 안정 실패)
* 잔존 감염/치석/치근면 오염
* 전신 상태(당뇨/면역저하 등)로 치유가 늦어짐
---
### 6) “사람 방문자” 관점의 팁(치과/건강 정보 페이지 운영 시)
엠도게인을 다루는 페이지를 운영한다면:
* **적응증을 좁게**(intrabony, furcation, recession) 설명하고, 일반 치주염 전체를 과대 포장하지 않는다. ([straumann.com][1])
* 금기/주의(당뇨 조절, 면역억제, 방사선 등)를 **안전문서 기반으로 명시**한다. ([straumann.com][4])
* 근거는 “치주낭/부착 개선” 중심으로 쓰고, “100% 재생” 같은 표현을 피한다. ([PMC][3])
이렇게 하면 의료정보로서 신뢰도를 올리고, 과장 광고 리스크를 줄인다.
---
## 日本語
### 概要
**エムドゲイン（Emdogain）**は、**エナメルマトリックス誘導体（EMD）**を用いた歯周組織再生材料で、手術中に清掃・処理した根面へ塗布し、**セメント質・歯根膜・歯槽骨**などの再生を促す目的で使われる。 ([straumann.com][1])
### 主な適応
* 垂直性骨欠損（intrabony defects）
* 2度根分岐部病変（Class II furcation）
* 一部の歯肉退縮（術式と組み合わせ） ([straumann.com][1])
### エビデンスの方向性
メタ解析/系統的レビューでは、intrabony欠損で**付着の改善・ポケット深さの減少**などが示され、GTRと同等傾向で合併症が少ないという整理もある。 ([PMC][3])
### 注意点（禁忌・リスク）
未コントロール糖尿病、免疫抑制や放射線治療など治癒を阻害する条件、感染・血流障害などは禁忌/注意として記載される。 ([straumann.com][4])
---
## Español
### Qué es
**Emdogain** (EMD) es un material biológico para **regeneración periodontal**, aplicado sobre la raíz limpiada durante cirugía para favorecer regeneración de **cemento, ligamento periodontal y hueso alveolar**. ([straumann.com][1])
### Para qué se usa
* Defectos intrabóseos
* Furcaciones clase II
* Recesiones seleccionadas ([straumann.com][1])
### Evidencia (qué suele mostrar)
Revisiones y meta-análisis reportan mejoras clínicas (ganancia de inserción, reducción de sondaje) frente a controles en intrabóseos; algunas síntesis encuentran resultados similares a GTR con menor complejidad/complicaciones en ensayos. ([PMC][3])
### Contraindicaciones/precauciones
Documentos de seguridad mencionan diabetes no controlada, condiciones/terapias que comprometen la cicatrización (inmunosupresión, radiación), esteroides crónicos a dosis altas, etc. ([straumann.com][4])
---
## Français
### Définition
**Emdogain (EMD)** est un matériau biologique de **régénération parodontale**, appliqué sur une surface radiculaire soigneusement préparée pendant une chirurgie, visant la régénération du **cément, ligament parodontal et os alvéolaire**. ([straumann.com][1])
### Indications fréquentes
* Défauts intra-osseux (intrabony)
* Furcations de classe II
* Certaines récessions (cas sélectionnés) ([straumann.com][1])
### Données cliniques (tendance générale)
Des revues/méta-analyses rapportent des améliorations cliniques vs contrôles pour les défauts intra-osseux; certaines synthèses concluent à des résultats comparables à la GTR avec une mise en œuvre plus simple et moins de complications dans les essais inclus. ([PMC][3])
### Sécurité / contre-indications
Les documents de sécurité listent des situations de prudence/contre-indication : diabète non contrôlé, états/traitements compromettant la cicatrisation (immunosuppression, radiothérapie), corticothérapie chronique à forte dose, etc. ([straumann.com][4])
---
## Extra: quick source map (so you know what is “official”)
* Meta-analyses / evidence synthesis: Cochrane-style review and meta-analysis summaries ([PMC][3])
* Official product information (Korean brochure): mechanism/indications/procedure overview ([straumann.com][1])
* Official safety/IFU-style documents: contraindications & precautions ([straumann.com][4])
* Regulatory document (U.S. FDA PMA): adverse events observed in trials (contextual) ([FDA Access Data][6])
If you meant a different “엠도게인” (a different product/term), the most common match in dentistry is **Emdogain® (EMD)** described above.
[1]: https://www.straumann.com/content/dam/media-center/straumann/ko-kr/documents/brochure/product-information/490.280_kr_Emdogain_low.pdf?utm_source=chatgpt.com "Straumann® Emdogain® for periodontal regeneration"
[2]: https://guiasclinicas.fundaciondental.es/wp-content/uploads/2018/03/Cita-49.pdf?utm_source=chatgpt.com "Enamel matrix derivative (Emdogain®) for periodontal ..."
[3]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6786880/?utm_source=chatgpt.com "Enamel matrix derivative (Emdogain®) for periodontal tissue ..."
[4]: https://www.straumann.com/content/dam/media-center/straumann/de-de/documents/material-data-safety-sheet/MSDS_Emdogain.pdf?utm_source=chatgpt.com "emdogain Sicherheitsdatenblatt"
[5]: https://www.hasystems.co.il/files/search/articles/Emdogain_FL_IFU__incl_Peri_implant_mucositis_%D7%90%D7%A0%D7%92%D7%9C%D7%99%D7%AA.pdf?utm_source=chatgpt.com "Instructions for use: Straumann® Emdogain® FL"
[6]: https://www.accessdata.fda.gov/cdrh_docs/pdf/p930021.pdf?utm_source=chatgpt.com "Premarket Approval of Biora AB - accessdata.fda.gov"
# 엠도게인(Emdogain, Enamel Matrix Derivative) — 정체·시술 방식·효과·주의점
---
## English
### 1) What “Emdogain” is
**Emdogain** is a periodontal regenerative material based on an **enamel matrix derivative (EMD)**—a protein mixture originally involved in tooth root development. Clinically, it’s applied to a cleaned root surface during periodontal surgery to help regenerate components of the periodontium such as **cementum, periodontal ligament, and alveolar bone**. ([straumann.com][1])
A practical way to think about it:
* It’s **not a “gum filler.”**
* It’s a **biologic regenerative adjunct** used in specific surgical cases where regeneration is plausible.
---
### 2) What it’s used for (typical indications)
Product/clinical materials commonly describe use in:
* **Intrabony defects** (vertical bone defects around teeth)
* **Class II furcation defects** (bone loss between roots of multi-rooted teeth)
* **Recession defects** (selected cases, often combined with flap techniques) ([straumann.com][1])
These are not “all gum problems.” They are specific defect types where regeneration is surgically attempted.
---
### 3) How it’s applied (high-level surgical workflow)
A typical workflow described in product information looks like:
1. **Raise a flap** to access the defect
2. **Thoroughly clean/debride** the root surface
3. **Condition the root surface** with EDTA gel (often sold as PrefGel) for a short period, then rinse
4. **Apply Emdogain** onto the prepared root/defect area
5. **Suture** for stable wound closure ([straumann.com][1])
Why these steps matter:
* Regeneration is very sensitive to **root surface cleanliness** and **wound stability** (micro-movement and contamination reduce success).
---
### 4) Does it work? (what evidence generally shows)
Evidence syntheses and systematic reviews report that, for **intrabony defects**, EMD/Emdogain provides statistically significant clinical improvements compared with open-flap debridement or controls, including gains in clinical attachment and reductions in probing depth at around 1 year. ([guiasclinicas.fundaciondental.es][2])
A major evidence summary (Cochrane-style review work) also reports EMD can show **similar clinical results to guided tissue regeneration (GTR)** while being simpler to use and associated with fewer complications in the studied trials, with no serious adverse reactions reported in those trials. ([PMC][3])
**What “works” means in reality**
* Usually: improved probing depth/attachment level + radiographic bone fill trends
* Not usually: “the gum grows back perfectly everywhere”
* Outcomes depend heavily on defect morphology, surgical technique, infection control, and patient factors (especially smoking and oral hygiene).
---
### 5) Safety, contraindications, and common complications
**Contraindications / caution situations** described in safety documentation include (examples):
* Uncontrolled diabetes or uncontrolled systemic disease
* Conditions/treatments compromising wound healing (e.g., immunosuppression, radiation)
* Chronic high-dose steroid therapy
* Bone metabolic diseases
* Infection or vascular impairment at the surgical site ([straumann.com][4])
**Side effects / complications**
Clinical documents note that adverse events reported tend to be **procedure-related** (bleeding, swelling, pain, inflammation) and that serious events are uncommon in trials; however, complications can occur as with periodontal surgery. ([PMC][3])
**Allergy / sensitivity**
Because EMD products are biologic derivatives, **hypersensitivity/allergic reactions are possible** (rare), and a known allergy to components would be a key red flag. (This is generally addressed in IFU/safety documentation language around adverse events and precautions.) ([hasystems.co.il][5])
Operationally, the biggest “risk” is often not systemic—it's **local failure of regeneration** due to contamination, flap instability, or poor plaque control.
---
### 6) Practical “should I do it?” decision logic (non-sales, clinical realism)
Emdogain tends to make sense when:
* The tooth is worth saving (strategic tooth)
* The defect type is suitable (especially intrabony defects)
* The clinician can achieve stable primary closure
* The patient can maintain excellent plaque control during healing
It tends to be less attractive when:
* The site cannot be kept clean during healing
* Severe systemic factors compromise wound healing (see contraindications)
* The defect morphology is unfavorable for regeneration
* Mobility/occlusion issues are uncontrolled
---
### 7) Implementation tips (for website owners running dental content pages)
If you publish health/dental info pages about Emdogain:
* Avoid absolute claims (“guaranteed regeneration”).
* Clearly separate **indications** (intrabony/furcation/recession) from general gum disease.
* Include a short “risks/contraindications” section (uncontrolled diabetes, immunosuppression, etc.) sourced from official docs. ([straumann.com][4])
This reduces misinformation risk and improves trust.
---
## 한국어
### 1) 엠도게인(Emdogain)이 뭔가
**엠도게인(Emdogain)**은 치주 재생 치료에 쓰이는 **법랑질 기질 유도체(EMD, Enamel Matrix Derivative)** 기반의 생물학적 재생 재료다. 치주 수술 중에 **깨끗이 정리한 치근면/골결손 부위**에 도포해서, **백악질·치주인대·치조골** 같은 치주조직 재생을 돕는다는 컨셉으로 사용된다. ([straumann.com][1])
핵심은 이거다:
* 잇몸을 “메우는” 게 아니라
* 특정 결손 형태에서 “재생”을 시도하는 **수술 보조 재료**다.
---
### 2) 어떤 경우에 쓰나(대표 적응증)
공식/제품 안내 자료에서 흔히 다루는 적용 부위는:
* **치조골 내 골결손(인트라보니, intrabony defects)**
* **2도 치근이개부 병소(Class II furcation)**
* **치은 퇴축(recession defects)**(선택적 케이스에서 술식과 함께) ([straumann.com][1])
즉 “치주염이면 무조건 엠도게인”이 아니라, **재생이 가능한 결손 형태**가 전제다.
---
### 3) 시술은 어떻게 진행되나(큰 흐름)
제품 안내서에서 설명되는 전형적인 흐름은:
1. 결손 부위 접근을 위해 **잇몸 절개/판막 형성**
2. 치근면·결손부의 **염증 조직/치석/오염 제거(디브리드먼트)**
3. EDTA 젤(예: PrefGel)을 일정 시간 적용 후 **세척**
4. 결손부에 **엠도게인 도포**
5. **봉합**으로 상처를 안정화 ([straumann.com][1])
왜 이렇게 하냐:
* 재생은 “약 바르면 끝”이 아니라, **치근면 컨디셔닝 + 상처 안정성(미세 움직임 최소화) + 청결 유지**가 결과를 크게 좌우한다.
---
### 4) 효과는 어느 정도인가(근거가 말하는 범위)
무작위 임상시험을 모아 분석한 리뷰/메타분석에서는, 특히 **intrabony 결손**에서 EMD가 단순 판막수술(또는 대조) 대비 **부착수준 개선, 치주낭 깊이 감소** 등의 유의미한 임상 개선을 보였다고 정리한다. ([guiasclinicas.fundaciondental.es][2])
또 다른 종합 근거에서는 EMD가 **GTR(유도조직재생술)**과 유사한 임상 결과를 보이면서도 술식이 단순하고 합병증이 적었다는 취지로 요약되며, 포함된 시험들에서는 심각한 이상반응이 보고되지 않았다고 정리한다. ([PMC][3])
현실적으로 “효과”의 의미:
* 치주낭 깊이(프로빙) 개선, 부착 수준 개선, 방사선상 골충전 경향
* 다만 “모든 부위에서 새 잇몸이 완벽히 복원” 같은 보장은 아니다.
* 결손 형태, 술자 숙련도, 봉합/판막 안정, 감염관리, 환자 위생이 성패를 가른다.
---
### 5) 부작용·금기·실패 패턴(운영자/환자 모두 알아야 하는 부분)
**금기/주의 상황 예시(공식 안전문서에 포함되는 범주)**
* 조절되지 않는 당뇨 등 **전신질환이 조절되지 않는 경우**
* 상처 치유를 방해하는 상태/치료(면역억제, 방사선 등)
* **고용량 스테로이드 장기요법**
* 골대사 질환
* 수술 부위 감염 또는 혈류장애 ([straumann.com][4])
**이상반응/합병증**
* 대부분은 치주 수술에 동반 가능한 **출혈, 부종, 통증, 염증** 같은 “시술 관련” 반응이 중심으로 보고되며, 임상시험 기반 요약에서는 심각한 이상반응이 흔하지 않았다고 정리된다. ([PMC][3])
**실패가 일어나는 가장 흔한 이유(현장형)**
* 환부가 오염됨(플라그 컨트롤 실패)
* 봉합이 불안정하거나 판막이 열림(상처 안정 실패)
* 잔존 감염/치석/치근면 오염
* 전신 상태(당뇨/면역저하 등)로 치유가 늦어짐
---
### 6) “사람 방문자” 관점의 팁(치과/건강 정보 페이지 운영 시)
엠도게인을 다루는 페이지를 운영한다면:
* **적응증을 좁게**(intrabony, furcation, recession) 설명하고, 일반 치주염 전체를 과대 포장하지 않는다. ([straumann.com][1])
* 금기/주의(당뇨 조절, 면역억제, 방사선 등)를 **안전문서 기반으로 명시**한다. ([straumann.com][4])
* 근거는 “치주낭/부착 개선” 중심으로 쓰고, “100% 재생” 같은 표현을 피한다. ([PMC][3])
이렇게 하면 의료정보로서 신뢰도를 올리고, 과장 광고 리스크를 줄인다.
---
## 日本語
### 概要
**エムドゲイン（Emdogain）**は、**エナメルマトリックス誘導体（EMD）**を用いた歯周組織再生材料で、手術中に清掃・処理した根面へ塗布し、**セメント質・歯根膜・歯槽骨**などの再生を促す目的で使われる。 ([straumann.com][1])
### 主な適応
* 垂直性骨欠損（intrabony defects）
* 2度根分岐部病変（Class II furcation）
* 一部の歯肉退縮（術式と組み合わせ） ([straumann.com][1])
### エビデンスの方向性
メタ解析/系統的レビューでは、intrabony欠損で**付着の改善・ポケット深さの減少**などが示され、GTRと同等傾向で合併症が少ないという整理もある。 ([PMC][3])
### 注意点（禁忌・リスク）
未コントロール糖尿病、免疫抑制や放射線治療など治癒を阻害する条件、感染・血流障害などは禁忌/注意として記載される。 ([straumann.com][4])
---
## Español
### Qué es
**Emdogain** (EMD) es un material biológico para **regeneración periodontal**, aplicado sobre la raíz limpiada durante cirugía para favorecer regeneración de **cemento, ligamento periodontal y hueso alveolar**. ([straumann.com][1])
### Para qué se usa
* Defectos intrabóseos
* Furcaciones clase II
* Recesiones seleccionadas ([straumann.com][1])
### Evidencia (qué suele mostrar)
Revisiones y meta-análisis reportan mejoras clínicas (ganancia de inserción, reducción de sondaje) frente a controles en intrabóseos; algunas síntesis encuentran resultados similares a GTR con menor complejidad/complicaciones en ensayos. ([PMC][3])
### Contraindicaciones/precauciones
Documentos de seguridad mencionan diabetes no controlada, condiciones/terapias que comprometen la cicatrización (inmunosupresión, radiación), esteroides crónicos a dosis altas, etc. ([straumann.com][4])
---
## Français
### Définition
**Emdogain (EMD)** est un matériau biologique de **régénération parodontale**, appliqué sur une surface radiculaire soigneusement préparée pendant une chirurgie, visant la régénération du **cément, ligament parodontal et os alvéolaire**. ([straumann.com][1])
### Indications fréquentes
* Défauts intra-osseux (intrabony)
* Furcations de classe II
* Certaines récessions (cas sélectionnés) ([straumann.com][1])
### Données cliniques (tendance générale)
Des revues/méta-analyses rapportent des améliorations cliniques vs contrôles pour les défauts intra-osseux; certaines synthèses concluent à des résultats comparables à la GTR avec une mise en œuvre plus simple et moins de complications dans les essais inclus. ([PMC][3])
### Sécurité / contre-indications
Les documents de sécurité listent des situations de prudence/contre-indication : diabète non contrôlé, états/traitements compromettant la cicatrisation (immunosuppression, radiothérapie), corticothérapie chronique à forte dose, etc. ([straumann.com][4])
---
## Extra: quick source map (so you know what is “official”)
* Meta-analyses / evidence synthesis: Cochrane-style review and meta-analysis summaries ([PMC][3])
* Official product information (Korean brochure): mechanism/indications/procedure overview ([straumann.com][1])
* Official safety/IFU-style documents: contraindications & precautions ([straumann.com][4])
* Regulatory document (U.S. FDA PMA): adverse events observed in trials (contextual) ([FDA Access Data][6])
If you meant a different “엠도게인” (a different product/term), the most common match in dentistry is **Emdogain® (EMD)** described above.
[1]: https://www.straumann.com/content/dam/media-center/straumann/ko-kr/documents/brochure/product-information/490.280_kr_Emdogain_low.pdf?utm_source=chatgpt.com "Straumann® Emdogain® for periodontal regeneration"
[2]: https://guiasclinicas.fundaciondental.es/wp-content/uploads/2018/03/Cita-49.pdf?utm_source=chatgpt.com "Enamel matrix derivative (Emdogain®) for periodontal ..."
[3]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6786880/?utm_source=chatgpt.com "Enamel matrix derivative (Emdogain®) for periodontal tissue ..."
[4]: https://www.straumann.com/content/dam/media-center/straumann/de-de/documents/material-data-safety-sheet/MSDS_Emdogain.pdf?utm_source=chatgpt.com "emdogain Sicherheitsdatenblatt"
[5]: https://www.hasystems.co.il/files/search/articles/Emdogain_FL_IFU__incl_Peri_implant_mucositis_%D7%90%D7%A0%D7%92%D7%9C%D7%99%D7%AA.pdf?utm_source=chatgpt.com "Instructions for use: Straumann® Emdogain® FL"
[6]: https://www.accessdata.fda.gov/cdrh_docs/pdf/p930021.pdf?utm_source=chatgpt.com "Premarket Approval of Biora AB - accessdata.fda.gov"